Andrew P Ambrosy, MD

People

Kaiser Permanente Division of Research
2000 Broadway
Oakland, CA 94612

(510) 891-3607 (phone)
andrew.p.ambrosy@kp.org

Andrew P. Ambrosy, MD, is a practicing cardiologist at Kaiser Permanente in San Francisco as well as research scientist within the Division of Research’s section on Cardiovascular and Metabolic Conditions. His research interests are ischemic heart disease, cardiomyopathy, and heart failure, and he has extensive prior experience in health outcomes, implementation science, and traditional and pragmatic clinical trials. He previously completed a dedicated research fellowship at Duke University Medical Center/Duke Clinical Research Institute where he was a member of the operations team for the National Heart, Lung, and Blood Institute-funded Heart Failure Network and several industry-sponsored clinical trials. He has presented his research at national and international scientific meetings and has authored approximately 100 peer-reviewed manuscripts.

Current Position(s):

Staff Cardiologist, Department of Cardiology, The Permanente Medical Group, San Francisco
Research Scientist, Division of Research, Kaiser Permanente Northern California

Section Affiliations:

Cardiovascular and Metabolic Conditions

Primary Research Interests:

Ischemia Heart Disease
Cardiomyopathy
Heart Failure
Health Outcomes
Implementation Science
Clinical Trials

Studies

Partnership for Anemia: Clinical and Translational Trials in the Elderly (PACTTE)

Within the CVRN-HF Network, and in collaboration with NIA-sponsored PACTTE consortium investigators, we will examine the following among a large, multi-center cohort of elderly patients with heart failure with reduced or preserved left ventricular systolic function: 1) to characterize the contemporary frequency of testing for and prevalence of anemia; 2) to assess the frequency, timing and extent of evaluation for reversible causes of anemia in those with documented anemia; 3) to evaluate contemporary adverse event rates by hemoglobin level; and 4) to examine the feasibility of conducting a potential pragmatic clinical trial of systematic evaluation of anemia in elderly heart failure patients.
Investigator: Ambrosy, Andrew; Go, Alan
Funder: National Institute on Aging

Highlighted Publications

No results found matching criteria

Publications

Left Ventricular Global Longitudinal Strain Can Reliably Be Measured from a Single Apical Four-Chamber View in Patients with Heart Failure

Author(s): Alenezi F; Ambrosy AP; Phelan M; Chiswell K; Abudaqa L; Alajmi H; Kisslo J; Velazquez EJ

J Am Soc Echocardiogr. 2018 Dec 11.

Current Position(s):

Section Affiliations:

Primary Research Interests:

Studies

Partnership for Anemia: Clinical and Translational Trials in the Elderly (PACTTE)

Highlighted Publications

Publications

Left Ventricular Global Longitudinal Strain Can Reliably Be Measured from a Single Apical Four-Chamber View in Patients with Heart Failure

Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure

Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial

Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure.

Undiagnosed dysglycemia in patients hospitalized for worsening heart failure: not so sweet after all.

Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.

Improving Postdischarge Outcomes in Acute Heart Failure.

Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status.

Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION.

Renal Function and Exercise Training in AmbulatoryHeart Failure Patients With a Reduced Ejection Fraction.

Combination drug therapy in heart failure: greater than the sum of its parts.

Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).

Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial.

The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions.

Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means.

Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial.

Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure.

Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.

Expanded algorithm for managing patients with acute decompensated heart failure.

Sudden cardiac death following admission for acute heart failure: adding insult to injury.

Lessons learned in acute heart failure.

Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF.

Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial.

Clinical profiles in acute heart failure: one size fits all or not at all?

Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement.

Adverse Remodeling and Reverse Remodeling After Myocardial Infarction.

Building the case for aerobic exercise in ambulatory patients with heart failure and a reduced ejection fraction.

Clinical trials in acute heart failure: beginning of the end or end of the beginning?

Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.

Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network).

Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial.

Reply: Factors That May Affect Body Change During and After Hospitalization for Acute Heart Failure.

Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials.

Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial.

Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial.

Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Targeting digoxin dosing to serum concentration: is the bullseye too small?

Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps.

Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.

Digoxin for Worsening Chronic Heart Failure: Underutilized and Underrated.

Natriuretic peptide-guided management in heart failure.

In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial.

Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure.

The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF.

Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations.

Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America: Exploring Acute Heart Failure Trials As a Case Study.

Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial.

Pulmonary Oedema-Therapeutic Targets.

International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry.

Effect of minor liver function test abnormalities and values within the normal range on survival in heart failure.

Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).

Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes.

Epidemiology, pathophysiology, and in-hospital management of pulmonary edema: data from the Romanian Acute Heart Failure Syndromes registry.

Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries.

Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial.

Patterns of intensive care unit admissions in patients hospitalized for heart failure: insights from the RO-AHFS registry.

The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions.

Lipids, statins, and clinical outcomes in heart failure: rethinking the data.

The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

The predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registry.

Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).

Not time to RELAX in acute heart failure.

Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Hepatic abscess with biliary communication following transarterial chemoembolization of hepatocellular carcinoma.

The disconnect between phase II and phase III trials of drugs for heart failure.

Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial.

Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.

Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial.

Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).

Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.